Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.32 |
| ▸ | ALB | P02768 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | TYK2 | P29597 | 1/20 | 0.32 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.31 |
| ▸ | MERTK | Q12866 | 1/20 | 0.31 |
| ▸ | GAS6 | Q14393 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10094116 | 0.83 | IRAK4 (0.36) | IRAK4NR1I2ALBPDE4DJAK1 | |
| SCHEMBL10093971 | 0.81 | IRAK4 (0.51) | IRAK4 | |
| SCHEMBL10094224 | 0.81 | PIK3CA (0.35) | IRAK4NR1I2ALBPDE4DJAK1 | |
| SCHEMBL10094076 | 0.81 | NR1I2 (0.32) | IRAK4NR1I2ALBPDE4DJAK1 | |
| SCHEMBL10094117 | 0.80 | IRAK4 (0.39) | IRAK4NR1I2ALBPDE4DJAK1 | |
| SCHEMBL10094094 | 0.80 | IRAK4 (0.31) | IRAK4NR1I2ALBPDE4DJAK1 | |
| SCHEMBL13492781 | 0.80 | IRAK4 (0.32) | IRAK4NR1I2ALBPDE4DSYK | |
| SCHEMBL13492718 | 0.79 | PIK3CA (0.42) | — | |
| SCHEMBL10094107 | 0.78 | NR1I2 (0.32) | NR1I2ALBPDE4DJAK1TYK2 | |
| SCHEMBL10094126 | 0.78 | IRAK4 (0.35) | IRAK4NR1I2ALBPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120107271-A1 | ETHYNYL-SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME LLC | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120107271-A1 | ETHYNYL-SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS | CYP2C9, P2RX3, F12 | IRAK4 951/4885NR1I2 113/4885ALB 2404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.